Shots:

• The companies collaborated to develop a tissue based KRAS Cdx test to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib- which is an investigational small molecule inhibitor of KRASG12
• The agreement initially focuses on developing CDx for NSCLC and allows to further development of tests for Mirati’s oncology programs
• The planned CDx would be a part of QIAGEN’s therascreen KRAS testing portfolio based on real-time qualitative PCR for the QIAGEN Rotor-Gene Q MDx instrument. Earlier- the companies collaborated to develop a CDx test to support glesatinib

  Ref: Businesswire | Image: Reuters